Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of the ratio of non-HDL-cholesterol to HDL-cholesterol with clinical and pathological characteristics in diabetic kidney disease.

BMC nephrology·2026
Same author

The versatile roles of long non-coding RNAs in kidney disease.

Nature reviews. Nephrology·2026
Same author

A Target Trial Emulation to Investigate Kidney Protection from Statin Initiation in Adults with Normal Kidney Function.

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial.

JAMA·2026
Same author

Global Treatment Patterns for Immunoglobulin A Nephropathy in Adults: Results from a Real-World Survey.

Glomerular diseases·2026
Same author

Current understanding of sodium-glucose transporter 2 inhibitors in cardiovascular-kidney-metabolic syndrome.

Frontiers in pharmacology·2026
Same journal

Adsorption of Pathogens and Blockade of Sepsis Cascade.

Contributions to nephrology·2023
Same journal

Hemoadsorption: Research Agenda and Potential Future Applications.

Contributions to nephrology·2023
Same journal

Hemoperfusion in Poisoning and Drug Overdose.

Contributions to nephrology·2023
Same journal

Hemoperfusion in Burns.

Contributions to nephrology·2023
Same journal

Sequential Extracorporeal Therapy in Sepsis.

Contributions to nephrology·2023
Same journal

The Use of Adsorption in Extracorporeal Liver Support: The Double Plasma Molecular Adsorption System (DPMAS).

Contributions to nephrology·2023
See all related articles

Related Experiment Video

Updated: May 11, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Hepatitis C virus-associated glomerulonephritis.

Sydney C W Tang1, Kar Neng Lai

  • 1Nephrology, Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China.

Contributions to Nephrology
|May 22, 2013
PubMed
Summary
This summary is machine-generated.

Hepatitis C virus (HCV) infection can cause kidney disease, specifically glomerulonephritis. While antiviral treatments exist, their effectiveness and safety for HCV-related kidney conditions require further study.

More Related Videos

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

Related Experiment Videos

Last Updated: May 11, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

Area of Science:

  • Nephrology
  • Hepatology
  • Virology

Background:

  • Hepatitis C virus (HCV) infection is a global health issue with frequent extrahepatic manifestations, including kidney disease.
  • Type I membranoproliferative glomerulonephritis associated with type II cryoglobulinemia is the most common HCV-related renal complication.
  • Pathogenesis involves immune complex deposition in the glomeruli.

Purpose of the Study:

  • To review the current understanding of HCV-related glomerulonephritis.
  • To discuss current treatment guidelines and emerging therapies.

Main Methods:

  • Literature review of existing studies and guidelines on HCV-related glomerulonephritis.
  • Analysis of the role of antiviral therapies, including interferon-based regimens and direct-acting antiviral agents (DAAs).

Main Results:

  • Standard and pegylated interferon-α with ribavirin are recommended for HCV-related glomerulopathies.
  • Direct-acting antiviral agents (DAAs) show promise and initial safety in end-stage renal disease (ESRD) patients.
  • Efficacy and safety data for DAAs specifically in HCV-related glomerulonephritis are currently limited.

Conclusions:

  • HCV-related glomerulonephritis necessitates antiviral treatment.
  • DAAs represent a significant advancement in HCV treatment, but more research is needed on their use in patients with HCV-related kidney disease.